Employees Retirement System of Texas decreased its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 37.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,300 shares of the company’s stock after selling 108,100 shares during the period. Employees Retirement System of Texas’ holdings in Eli Lilly And Co were worth $20,749,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the stock. Athena Capital Advisors LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth approximately $26,000. Larson Financial Group LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth approximately $29,000. Ironwood Financial llc acquired a new position in Eli Lilly And Co during the 4th quarter worth approximately $30,000. Acima Private Wealth LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth approximately $33,000. Finally, Essex Investment Management Co. LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth approximately $34,000. Institutional investors own 77.00% of the company’s stock.
Shares of Eli Lilly And Co stock opened at $123.08 on Friday. The company has a market capitalization of $127.87 billion, a PE ratio of 22.18, a P/E/G ratio of 2.49 and a beta of 0.33. Eli Lilly And Co has a 52 week low of $74.51 and a 52 week high of $130.75. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the consensus estimate of $1.36 by ($0.03). The company had revenue of $6.44 billion during the quarter, compared to analysts’ expectations of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the company earned $1.14 earnings per share. On average, equities research analysts predict that Eli Lilly And Co will post 5.62 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 8th. Stockholders of record on Friday, February 15th were paid a $0.645 dividend. The ex-dividend date was Thursday, February 14th. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 annualized dividend and a dividend yield of 2.10%. Eli Lilly And Co’s dividend payout ratio is 46.49%.
A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Eli Lilly And Co in a research note on Tuesday. They set an “overweight” rating and a $140.00 price target on the stock. Citigroup set a $124.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a research note on Tuesday, February 26th. UBS Group dropped their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research note on Friday, February 8th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Finally, Barclays reissued a “buy” rating and issued a $130.00 price objective on shares of Eli Lilly And Co in a research note on Sunday, January 20th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $113.06.
In related news, insider Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $127.01, for a total transaction of $127,010.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 51,766 shares of the stock in a transaction that occurred on Tuesday, January 15th. The shares were sold at an average price of $117.74, for a total value of $6,094,928.84. Following the sale, the insider now directly owns 117,963,538 shares of the company’s stock, valued at $13,889,026,964.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 833,190 shares of company stock valued at $102,388,102. Company insiders own 0.11% of the company’s stock.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: How to calculate the intrinsic value of a stock
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.